COAG MEXC RealStocks
Own real COAG shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 20:07:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Hemab Therapeutics Holdings, Inc. (COAG) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $38.82, with a market capitalization of $1.91B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.00 to $55.42. This page covers its latest market performance, valuation, price trends and company information.
$1.91B | |
$41.50 | |
$43.94 | |
$38.26 | |
$40.86 | |
265.44K | |
498.95K | |
-- | |
$55.42 | |
$23.00 | |
-- | |
-- |
Hemab Therapeutics Holdings, Inc. (COAG) is currently trading at $38.82 as of 2026-11-16 19:50:15, down 4.60% ($1.88) from the previous close of $40.86
During today's regular trading session, COAG has traded between $38.26 and $43.94, with a trading volume of 265.44K shares. The current price is near the lower end of today's range.
Over the past seven days, Hemab Therapeutics Holdings, Inc. (COAG) moved from $45.57 to $38.82, representing a decline of 14.82% ($6.75).
The stock traded between $35.00 and $50.22 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 611.53 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 48.8%
COAG is currently trading at $38.82, placing it 48.8% of the way from its 52-week low of $23.00 to its 52-week high of $55.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Hemab Therapeutics Holdings, Inc. (COAG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to COAG, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between COAG shares and USD.
COAG Shares to USD
1.00 COAG shares = 38.816 USD
Calculations are estimates based on the latest available price and are for reference only.